AbbVie has announced new clinical data from its antibody-drug conjugate (ADC) platform, reinforcing its commitment to advancing targeted therapies for solid tumours.

The data was presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin in October.

The company’s investigational ADCs, including telisotuzumab adizutecan (Temab-A) and ABBV-706, demonstrated encouraging results across pancreatic, colorectal and other solid tumour types. AbbVie also shared updates on Emrelis (telisotuzumab vedotin), which is already approved for certain indications.

Daejin Abidoye, Vice President, Therapeutic Area Head, Oncology, Solid Tumour and Haematology, said: “We are excited to share new data from our growing ADC portfolio at ESMO 2025, including promising results from our investigational therapies telisotuzumab adizutecan and ABBV-706.

“These data reinforce our commitment to advancing novel targeted therapies for patients with difficult-to-treat cancers.”

The company highlighted that its ADCs are designed to deliver potent cytotoxic agents directly to cancer cells, potentially improving efficacy while limiting systemic toxicity. The phase 1 and phase 2 studies presented include data on safety, tolerability and preliminary efficacy.

AbbVie explained that the results support further development of its ADC candidates and underscore the potential of targeted approaches in oncology. The company’s pipeline continues to expand, with multiple ADCs in various stages of clinical development.

Abidoye added: “We remain focused on developing innovative therapies that have the potential to transform standards of care and improve outcomes for patients.”
The data presented at ESMO 2025 are expected to inform future clinical strategies and regulatory discussions, as AbbVie aims to strengthen its position in the oncology space.

Kainos has announced a new contract of up to three years with NHS England to enhance digital preventative healthcare services across the country.

The agreement, awarded through NHS England’s Digital Prevention Service Portfolio (DPSP), aims to improve access to vaccinations and screenings via the NHS App and accelerate delivery of personalised care in line with the NHS 10 Year Health Plan.

The partnership will see Kainos scale the Digital NHS Health Check service, allowing citizens to complete health assessments and receive tailored advice from home. Additional digital resources will support self-care, including mental health tools, weight management support and diabetes risk reduction pathways.

Key initiatives under the contract include the Vaccinations & Screening Clinical Record, which will give users a clear view of their vaccination and screening status through the NHS App to encourage uptake and early detection.

The Vaccinations Digital Services will also be maintained and enhanced to support more efficient rollout, better uptake and reduced inequalities.

Personalised Prevention Services will be expanded, including the new NHS Health Check and improved access to weight management services, talking therapies and lifestyle support.

Kainos and its partners – Public Digital, Baringa, Healthia, Helix Centre, Scroll and ETHOS – will work within NHS England product teams, contributing engineering, user-centred design and data expertise to improve live services and support the wider DPSP strategy.

Daniel Kemp, Healthcare Director at Kainos said: “We have a long history of supporting both NHS England and the NHS Digital Prevention Service, and we’re proud to be extending our partnership to advance this important shift towards proactive, preventative care.

“By scaling digital health checks, extending access to vaccinations and screenings, and embedding preventative support into everyday NHS care pathways, we are helping the NHS to deliver more personalised and accessible care, reduce pressure on frontline services, and improve health outcomes across the country.”